¼¼°èÀÇ ÀڱñÙÁ¾ Ä¡·á ±â±â ½ÃÀå
Uterine Fibroid Treatment Devices
»óǰÄÚµå : 1757888
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 276 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÀڱñÙÁ¾ Ä¡·á ±â±â ½ÃÀåÀº 2030³â±îÁö 81¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 53¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÀڱñÙÁ¾ Ä¡·á ±â±â ½ÃÀåÀº 2024-2030³â¿¡ CAGR 7.4%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 81¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¿Ü°ú¼ö¼úÀº CAGR 8.7%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 53¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀýÁ¦ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 5.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 14¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀڱñÙÁ¾ Ä¡·á ±â±â ½ÃÀåÀº 2024³â¿¡ 14¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 17¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 11.8%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.6%¿Í 7.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ "ÀڱñÙÁ¾ Ä¡·á ±â±â" ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

÷´Ü ÀڱñÙÁ¾ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÀÚ±ÃÀÇ ¾ç¼º Á¾¾çÀÎ ÀڱñÙÁ¾¿¡ ´ëÇÑ Àü ¼¼°è ºÎ´ãÀÌ Å©°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, 50¼¼±îÁö ¿©¼ºÀÇ 70-80%°¡ ÀڱñÙÁ¾À» ¾Î°í ÀÖÀ¸¸ç, Áõ»óÀÌ ÀÖ´Â °æ¿ì ´ë·® ÃâÇ÷, °ñ¹ÝÅë, ºÒÀÓ ¹× ±âŸ ÇÕº´ÁõÀ» À¯¹ßÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßº´·ü Áõ°¡´Â ƯÈ÷ Àڱà º¸Á¸ ¼ö¼úÀ» ¿øÇÏ´Â °¡Àӱ⠿©¼ºÀÇ °æ¿ì, È¿°úÀûÀÌ°í ´ú ħ½ÀÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¿¡ Á÷Á¢ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¿ª»çÀûÀ¸·Î ÀÚ±ÃÀûÃâ¼úÀÌ Ä¡·áÀÇ ÁÖ·ù¿´À¸³ª, ȯÀÚµéÀÇ ¼±È£µµ´Â ÀڱñÙÁ¾ ÀûÃâ¼ú, Àڱõ¿¸Æ»öÀü¼ú(UAE), º¹°­°æ ¼ö¼ú ¹× ·Îº¿ º¸Á¶ ¼ö¼ú°ú °°Àº Àúħ½ÀÀû ¼ö¼ú°ú °°Àº Àڱà º¸Á¸ ¼ö¼ú·Î Á¡Á¡ ´õ ¸¹ÀÌ À̵¿Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ »ý½Ä·ÂÀ» Áß½ÃÇÏ´Â ¹®È­±Ç¿¡¼­ Àڱà ÀûÃâ¼ú¿¡ ´ëÇÑ ³«Àΰú »çȸÀû Àǹ̴ ÀÌ·¯ÇÑ ÀüȯÀ» ´õ¿í °¡¼ÓÈ­½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ýȰ½À°üÀÇ º¯È­, ´ÊÀº ÀӽŠ±â°£, ºñ¸¸ÀÌ À§ÇèÀ» Áõ°¡½ÃŰ´Â ¿äÀÎÀ¸·Î È®ÀεǾî Á¶±â Áø´Ü°ú Ä¡·á·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÇコÄÉ¾î »ê¾÷ÀÌ ¿©¼º °Ç°­¿¡ ÃÊÁ¡À» ¸ÂÃß°í, ÀÎ½Ä °³¼± Ä·ÆäÀÎÀÌ °­È­µÇ¸é¼­ °ËÁøÀ²°ú Áø´ÜÀ²ÀÌ ±ÞÁõÇϰí ÀÖ´Â °Íµµ ÀڱñÙÁ¾ Ä¡·á ±â±â ½ÃÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

±â¼ú°ú Çõ½ÅÀº ¾î¶»°Ô Ä¡·á¹ýÀ» ÀçÁ¤ÀÇÇϰí Àִ°¡?

Çõ½ÅÀûÀÎ Çõ½ÅÀÌ ÀڱñÙÁ¾ °ü¸®ÀÇ ÁøÈ­ÀÇ Á߽ɿ¡ ÀÖÀ¸¸ç, ÀÇ·á±â±â Á¦Á¶¾÷üµéÀº ÀÓ»ó °á°ú¸¦ °³¼±Çϰí, ȸº¹ ±â°£À» ´ÜÃàÇϸç, ¼ö¼ú ÇÕº´ÁõÀ» ÁÙÀ̱â À§ÇØ ÃÖ÷´Ü Àåºñ¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. °í¹ÐµµÁý¼ÓÃÊÀ½ÆÄ(HIFU), °íÁ֯ļÒÀÛ¼ú(RFA), MRI À¯µµÇÏ Áý¼ÓÃÊÀ½ÆÄ¼ö¼ú(MRgFUS)°ú °°Àº Ä¡·á ±â¼úÀº ºñħ½ÀÀû ¶Ç´Â Àúħ½ÀÀû Ä¡·á Á¢±Ù¹ýÀ» ÀçÁ¤ÀÇÇϰí ÀÖ½À´Ï´Ù. ÀÌ ÀåºñµéÀº ÁÖº¯ Á¶Á÷ ¼Õ»ó ¾øÀÌ ÀڱñÙÁ¾À» Á¤È®ÇÏ°Ô Á¶ÁØÇÒ ¼ö ÀÖÀ¸¸ç, ȯÀÚ¿¡°Ô ºÎÀÛ¿ëÀÌ Àû°í ºü¸¥ ¿ÏÈ­¿Í ¿Ü·¡ ȯÀÚ ¼öÁØÀÇ ÆíÀǼºÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ º¹°­°æ ÆÄ¿ö¸ô¼¼·¹ÀÌÅÍ¿Í Ã·´Ü ÀÚ±Ã°æ ±â±¸´Â ƯÈ÷ Á¶Á÷ ÆÄÁ¾¿¡ ´ëÇÑ °ú°ÅÀÇ ¿ì·Á¿¡ ºñÃß¾î ¾ÈÀü¼ºÀ» Çâ»ó½Ã۱â À§ÇØ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ·Îº¿ ¼ö¼ú ½Ã½ºÅÛÀº °í°¡À̱ä ÇÏÁö¸¸ º¹ÀâÇÑ ÀڱñÙÁ¾ Á¦°ÅÀÇ Á¤È®µµ¸¦ ³ôÀ̱â À§ÇØ 3Â÷ ÀÇ·á º´¿ø¿¡¼­ äÅõǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû ¹ßÀüÀº ÀÇ»çµéÀÇ ½Å·Ú¸¦ ³ôÀÏ »Ó¸¸ ¾Æ´Ï¶ó, ÀúÃþ º´¿ø°ú ¿Ü·¡ Áø·á¼Ò±îÁö Ä¡·áÀÇ °¡´É¼ºÀ» ³ÐÇô ¾çÁúÀÇ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ¹ÎÁÖÈ­Çϰí ÀÖ½À´Ï´Ù.

Á¢±Ù¼ºÀ» È®´ëÇϱâ À§ÇØ ÀÇ·á ½Ã½ºÅÛ°ú ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ¹«¾ùÀ» Çϰí Àִ°¡?

ÀڱñÙÁ¾ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀº Á¤Ã¥Àû ³ë·Â, º¸Çè Àû¿ë °³Çõ, ÁøÈ­ÇÏ´Â ÀÓ»ó °¡À̵å¶óÀÎÀÇ Á¶ÇÕ¿¡ ÀÇÇØ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. °í¼Òµæ ±¹°¡¿¡¼­´Â Àúħ½ÀÀû ¿Ü·¡ Ä¡·á°¡ º¸Çè Àû¿ëÀ» ¹ÞÀ½À¸·Î½á ºñ¿ëÀÌ ³·¾ÆÁö°í Ä¡·á Á¢±Ù¼ºÀÌ ³ô¾ÆÁ³½À´Ï´Ù. ÇöÀç ¸¹Àº Á¤ºÎ ¹× ¹Î°£ ÀÇ·á±â°üÀº ÀڱñÙÁ¾ Ä¡·á¸¦ Çʼö ¿©¼º °Ç°­ÄɾîÀÇ ÀϺηΠºÐ·ùÇÏ¿© Áø´Ü, ÀÇ·Ú ¹× º¸Á¶±Ý Áö¿ø ÇÁ·Î¼¼½º¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ÁßÀú¼Òµæ±¹°¡(LMICs)´Â À̵¿½Ä Áø´Ü Àåºñ¿¡ ´ëÇÑ ÅõÀÚ, ºÎÀΰú ¿Ü°úÀÇ»ç ¿¬¼ö ÇÁ·Î±×·¥, ÀÎ½Ä °³¼±À» À§ÇÑ °øÁߺ¸°Ç Ä·ÆäÀÎ µîÀ» ÅëÇØ µÚóÁø ºÎºÐÀ» ȸº¹Çϰí ÀÖ½À´Ï´Ù. ´Ù±¹Àû NGO¿Í ¼¼°èº¸°Ç±â±¸µµ ÀÇ·á ¼±±³¿¡ ÀÚ±ÝÀ» Áö¿øÇϰųª Áö¹æ º´¿ø¿¡ Àåºñ¸¦ ±âÁõÇÏ´Â µî ¿ª·® °³¹ß¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ º´¿øÀº ºÎÀΰú, ¿µ»óÀÇÇаú, ÅëÁõ °ü¸®¸¦ °áÇÕÇÑ ´ÙÇÐÁ¦Àû ÀڱñÙÁ¾ Ŭ¸®´ÐÀ» ÅëÇÕÇÏ¿© ȯÀÚ°¡ ±Ù°Å¿¡ ±â¹ÝÇÑ ÀûÀýÇÑ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï ÀüÀÎÀû Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ¿Ü·¡ Ä¡·á¿Í ´çÀÏ Åð¿ø ÇÁ·ÎÅäÄÝ·Î ÀüȯÇÏ¿© º´¿øÀÇ ÀÚ¿øÀ» ÃÖÀûÈ­Çϰí ȯÀÚÀÇ ºÎ´ãÀ» ÁÙÀ̰í ÀÖ½À´Ï´Ù.

ÀڱñÙÁ¾ Ä¡·á±â±â ½ÃÀåÀÇ ±Þ¼ºÀå ¿øµ¿·ÂÀº?

ÀڱñÙÁ¾ Ä¡·á ±â±â ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ÀÓ»ó °üÇà, ȯÀÚ ¼±È£µµ¿Í ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ´Â ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ºñħ½ÀÀû, Àúħ½ÀÀû ±â±âÀÇ º¸±ÞÀ¸·Î ÀüÅëÀûÀÎ °³º¹ ¼ö¼ú¿¡¼­ Ä¡·á ÆÐÅÏÀÌ Å©°Ô º¯È­Çϰí ÀÖÀ¸¸ç, Á¶±â ȸº¹°ú °¡ÀÓ·Â º¸Á¸À» ¿øÇϴ ȯÀÚµéÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °æÁúÃÊÀ½ÆÄ³ª MRI¿Í °°Àº ¿µ»ó Áø´Ü ±â¼úÀÇ Çâ»óÀ¸·Î Áø´Ü »ç·ÊÀÇ È®´ëµµ ¼ö¼ú °Ç¼ö¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÀڱñÙÁ¾¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿©¼ºµéÀº Á¶±â °³ÀÔ°ú ÀÚ±ÃÀûÃâ¼ú¿¡ ´ëÇÑ ´ë¾ÈÀ» Àû±ØÀûÀ¸·Î ã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹Î°£ ¹× °ø°ø ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ½Ã¼úÀÇ È¿À²¼º°ú ºñ¿ë ´ëºñ È¿°ú¼ºÀÌ ¶Ù¾î³ª±â ¶§¹®¿¡ ÀڱñÙÁ¾ Ä¡·á Àåºñ¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ƯÈ÷ ºÏ¹Ì¿Í ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ¿Ü·¡ ¹× ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)ÀÇ Á¸Àç°¨ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó »õ·Î¿î Ä¡·á ÀåºñÀÇ »ó¾÷Àû ÀáÀç·ÂÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·áºñ ÁöÃâ Áõ°¡, Ãâ»ê Áö¿¬°ú °°Àº Àα¸ Åë°èÇÐÀû º¯È­, ºñ¸¸°ú È£¸£¸ó Àå¾Ö ¹ß»ý·ü Áõ°¡´Â ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇյǾî ÇâÈÄ ¼ö³â°£ Áö¼ÓÀûÀÎ ½ÃÀå È®´ë¸¦ À§ÇÑ °ß°íÇÏ°í ´Ù°¢ÀûÀÎ ±â¹ÝÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

±â¼ú(¿Ü°ú¼ö¼ú, ÀýÁ¦), Ä¡·á ¸ðµå(ħ½ÀÀû, Àúħ½ÀÀû, ºñħ½ÀÀû)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 42»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Uterine Fibroid Treatment Devices Market to Reach US$8.1 Billion by 2030

The global market for Uterine Fibroid Treatment Devices estimated at US$5.3 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Surgical, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Ablation segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.8% CAGR

The Uterine Fibroid Treatment Devices market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 11.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global "Uterine Fibroid Treatment Devices" Market - Key Trends & Drivers Summarized

Why Is There a Rising Demand for Advanced Uterine Fibroid Treatments?

The global burden of uterine fibroids-benign tumors of the uterus-has grown substantially, affecting up to 70-80% of women by the age of 50, with symptomatic cases leading to heavy bleeding, pelvic pain, infertility, and other complications. This rising incidence is directly influencing the demand for effective, less invasive treatment modalities, particularly in reproductive-age women who seek uterine-sparing procedures. Historically, hysterectomy was the dominant treatment; however, patient preference is increasingly shifting toward uterus-preserving alternatives such as myomectomy, uterine artery embolization (UAE), and minimally invasive surgeries like laparoscopic and robotic-assisted interventions. The stigma and social implications of undergoing hysterectomy-especially in cultures where fertility is highly valued-are reinforcing this transition. In addition, lifestyle changes, late pregnancies, and obesity have been identified as risk-enhancing factors, leading to earlier diagnosis and treatment. The healthcare industry’s increased focus on women’s health and a surge in screening and diagnostic rates, due in part to better awareness campaigns, are further propelling the market for uterine fibroid treatment devices.

How Are Technology and Innovation Redefining Treatment Modalities?

Innovative breakthroughs are at the heart of the evolution in uterine fibroid management, with medical device manufacturers introducing cutting-edge equipment designed to improve clinical outcomes, shorten recovery periods, and reduce surgical complications. Technologies such as high-intensity focused ultrasound (HIFU), radiofrequency ablation (RFA), and MRI-guided focused ultrasound surgery (MRgFUS) are redefining non-invasive or minimally invasive treatment approaches. These devices enable precise targeting of fibroids without damaging surrounding tissues, offering patients rapid relief with fewer side effects and outpatient-level convenience. Additionally, laparoscopic power morcellators and advanced hysteroscopic tools are being refined to improve safety, especially in light of past concerns around tissue dissemination. Robotic surgical systems, though expensive, are increasingly employed in tertiary care hospitals to improve accuracy in complex fibroid removal. These technological advancements are not only increasing physician confidence but are also expanding treatment availability to lower-tier hospitals and outpatient clinics, democratizing access to quality care.

What Are Healthcare Systems and Providers Doing to Expand Access?

Access to fibroid treatment is being shaped by a combination of policy efforts, insurance coverage reforms, and evolving clinical guidelines. In high-income countries, broader insurance inclusion of less invasive and outpatient procedures has helped bring down costs and improve uptake. Many governments and private providers are now classifying uterine fibroid treatments as part of essential women’s healthcare, leading to better diagnosis, referral, and subsidization processes. At the same time, low- and middle-income countries (LMICs) are catching up, with investments in mobile diagnostic units, training programs for gynecologic surgeons, and public health campaigns aimed at raising awareness. Multinational NGOs and global health organizations are also contributing to capacity building by funding medical missions and donating devices to rural hospitals. Furthermore, hospitals are integrating multidisciplinary fibroid clinics combining gynecology, radiology, and pain management to offer holistic care, ensuring that patients receive tailored, evidence-based treatment options. The shift toward outpatient care and same-day discharge protocols is also optimizing hospital resources and reducing patient burden.

What’s Driving the Escalating Growth in the Uterine Fibroid Treatment Devices Market?

The growth in the uterine fibroid treatment devices market is driven by several factors closely linked to technology evolution, clinical practices, and patient preferences. The widespread availability of non-invasive and minimally invasive devices is dramatically shifting treatment patterns away from traditional open surgery, attracting a larger volume of patients seeking faster recovery and fertility preservation. The expanding pool of diagnosed cases-due to improved imaging techniques like transvaginal ultrasound and MRI-is also increasing procedural volumes. Patient behavior is playing a pivotal role; as awareness about fibroids rises, women are actively seeking early intervention and alternatives to hysterectomy. Additionally, private and public healthcare providers are increasingly investing in device-based fibroid treatments due to their procedural efficiency and favorable cost-benefit ratios. The increasing presence of outpatient and ambulatory surgery centers, particularly in North America and parts of Asia-Pacific, is expanding the commercial viability of newer treatment devices. Rising healthcare spending, demographic shifts such as delayed childbirth, and higher incidences of obesity and hormonal disorders are further fueling demand. Together, these factors form a robust and multifaceted foundation for sustained market expansion in the years ahead.

SCOPE OF STUDY:

The report analyzes the Uterine Fibroid Treatment Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Surgical, Ablation); Mode of Treatment (Invasive, Minimally Invasive, Non-Invasive)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â